In the area of dyslipidemia management, the company is focusing on developing compounds that target the CD36 membrane receptor and inhibit the accumulation of lipid loaded cells at the site of atherosclerosis lesions.

Regarding type II diabetes, ARTERIA is rejuvenating major products such as Metformin through the development of new enhanced compounds.